Rain Therapeutics Alpha and Beta Analysis
| RAINDelisted Stock | USD 1.41 0.01 0.70% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rain Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rain Therapeutics over a specified time horizon. Remember, high Rain Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rain Therapeutics' market risk premium analysis include:
Beta 0.73 | Alpha (0.71) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rain |
Rain Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rain Therapeutics market risk premium is the additional return an investor will receive from holding Rain Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rain Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rain Therapeutics' performance over market.| α | -0.71 | β | 0.73 |
Rain Therapeutics Fundamentals Vs Peers
Comparing Rain Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rain Therapeutics' direct or indirect competition across all of the common fundamentals between Rain Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rain Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Rain Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Rain Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rain Therapeutics to competition |
| Fundamentals | Rain Therapeutics | Peer Average |
| Return On Equity | -0.97 | -0.31 |
| Return On Asset | -0.52 | -0.14 |
| Current Valuation | (32.85 M) | 16.62 B |
| Shares Outstanding | 27.58 M | 571.82 M |
| Shares Owned By Insiders | 16.48 % | 10.09 % |
| Shares Owned By Institutions | 68.38 % | 39.21 % |
| Number Of Shares Shorted | 661.11 K | 4.71 M |
Rain Therapeutics Opportunities
Rain Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Rain Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rain or other delisted stocks. Alpha measures the amount that position in Rain Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Rain Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Rain Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rain Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rain Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rain Therapeutics. Please utilize our Beneish M Score to check the likelihood of Rain Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rain Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Rain Stock
If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |